Cargando…
Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor
BACKGROUND: Increased endocannabinoid tonus by dual-action fatty acid amide hydrolase (FAAH) and substrate selective cyclooxygenase (COX-2) inhibitors is a promising approach for pain-relief. One such compound with this profile is 2-(2-fluorobiphenyl-4-yl)-N-(3-methylpyridin-2-yl)propanamide (Flu-AM...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4583449/ https://www.ncbi.nlm.nih.gov/pubmed/26406890 http://dx.doi.org/10.1371/journal.pone.0139212 |
_version_ | 1782391851210244096 |
---|---|
author | Gouveia-Figueira, Sandra Karlsson, Jessica Deplano, Alessandro Hashemian, Sanaz Svensson, Mona Fredriksson Sundbom, Marcus Congiu, Cenzo Onnis, Valentina Fowler, Christopher J. |
author_facet | Gouveia-Figueira, Sandra Karlsson, Jessica Deplano, Alessandro Hashemian, Sanaz Svensson, Mona Fredriksson Sundbom, Marcus Congiu, Cenzo Onnis, Valentina Fowler, Christopher J. |
author_sort | Gouveia-Figueira, Sandra |
collection | PubMed |
description | BACKGROUND: Increased endocannabinoid tonus by dual-action fatty acid amide hydrolase (FAAH) and substrate selective cyclooxygenase (COX-2) inhibitors is a promising approach for pain-relief. One such compound with this profile is 2-(2-fluorobiphenyl-4-yl)-N-(3-methylpyridin-2-yl)propanamide (Flu-AM1). These activities are shown by Flu-AM1 racemate, but it is not known whether its two single enantiomers behave differently, as is the case towards COX-2 for the parent flurbiprofen enantiomers. Further, the effects of the compound upon COX-2-derived lipids in intact cells are not known. METHODOLOGY/PRINCIPAL FINDINGS: COX inhibition was determined using an oxygraphic method with arachidonic acid and 2-arachidonoylglycerol (2-AG) as substrates. FAAH was assayed in mouse brain homogenates using anandamide (AEA) as substrate. Lipidomic analysis was conducted in unstimulated and lipopolysaccharide + interferon γ- stimulated RAW 264.7 macrophage cells. Both enantiomers inhibited COX-2 in a substrate-selective and time-dependent manner, with IC(50) values in the absence of a preincubation phase of: (R)-Flu-AM1, COX-1 (arachidonic acid) 6 μM; COX-2 (arachidonic acid) 20 μM; COX-2 (2-AG) 1 μM; (S)-Flu-AM1, COX-1 (arachidonic acid) 3 μM; COX-2 (arachidonic acid) 10 μM; COX-2 (2-AG) 0.7 μM. The compounds showed no enantiomeric selectivity in their FAAH inhibitory properties. (R)-Flu-AM1 (10 μM) greatly inhibited the production of prostaglandin D(2) and E(2) in both unstimulated and lipopolysaccharide + interferon γ- stimulated RAW 264.7 macrophage cells. Levels of 2-AG were not affected either by (R)-Flu-AM1 or by 10 μM flurbiprofen, either alone or in combination with the FAAH inhibitor URB597 (1 μM). CONCLUSIONS/SIGNIFICANCE: Both enantiomers of Flu-AM1 are more potent inhibitors of 2-AG compared to arachidonic acid oxygenation by COX-2. Inhibition of COX in lipopolysaccharide + interferon γ- stimulated RAW 264.7 cells is insufficient to affect 2-AG levels despite the large induction of COX-2 produced by this treatment. |
format | Online Article Text |
id | pubmed-4583449 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-45834492015-10-02 Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor Gouveia-Figueira, Sandra Karlsson, Jessica Deplano, Alessandro Hashemian, Sanaz Svensson, Mona Fredriksson Sundbom, Marcus Congiu, Cenzo Onnis, Valentina Fowler, Christopher J. PLoS One Research Article BACKGROUND: Increased endocannabinoid tonus by dual-action fatty acid amide hydrolase (FAAH) and substrate selective cyclooxygenase (COX-2) inhibitors is a promising approach for pain-relief. One such compound with this profile is 2-(2-fluorobiphenyl-4-yl)-N-(3-methylpyridin-2-yl)propanamide (Flu-AM1). These activities are shown by Flu-AM1 racemate, but it is not known whether its two single enantiomers behave differently, as is the case towards COX-2 for the parent flurbiprofen enantiomers. Further, the effects of the compound upon COX-2-derived lipids in intact cells are not known. METHODOLOGY/PRINCIPAL FINDINGS: COX inhibition was determined using an oxygraphic method with arachidonic acid and 2-arachidonoylglycerol (2-AG) as substrates. FAAH was assayed in mouse brain homogenates using anandamide (AEA) as substrate. Lipidomic analysis was conducted in unstimulated and lipopolysaccharide + interferon γ- stimulated RAW 264.7 macrophage cells. Both enantiomers inhibited COX-2 in a substrate-selective and time-dependent manner, with IC(50) values in the absence of a preincubation phase of: (R)-Flu-AM1, COX-1 (arachidonic acid) 6 μM; COX-2 (arachidonic acid) 20 μM; COX-2 (2-AG) 1 μM; (S)-Flu-AM1, COX-1 (arachidonic acid) 3 μM; COX-2 (arachidonic acid) 10 μM; COX-2 (2-AG) 0.7 μM. The compounds showed no enantiomeric selectivity in their FAAH inhibitory properties. (R)-Flu-AM1 (10 μM) greatly inhibited the production of prostaglandin D(2) and E(2) in both unstimulated and lipopolysaccharide + interferon γ- stimulated RAW 264.7 macrophage cells. Levels of 2-AG were not affected either by (R)-Flu-AM1 or by 10 μM flurbiprofen, either alone or in combination with the FAAH inhibitor URB597 (1 μM). CONCLUSIONS/SIGNIFICANCE: Both enantiomers of Flu-AM1 are more potent inhibitors of 2-AG compared to arachidonic acid oxygenation by COX-2. Inhibition of COX in lipopolysaccharide + interferon γ- stimulated RAW 264.7 cells is insufficient to affect 2-AG levels despite the large induction of COX-2 produced by this treatment. Public Library of Science 2015-09-25 /pmc/articles/PMC4583449/ /pubmed/26406890 http://dx.doi.org/10.1371/journal.pone.0139212 Text en © 2015 Gouveia-Figueira et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Gouveia-Figueira, Sandra Karlsson, Jessica Deplano, Alessandro Hashemian, Sanaz Svensson, Mona Fredriksson Sundbom, Marcus Congiu, Cenzo Onnis, Valentina Fowler, Christopher J. Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor |
title | Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor |
title_full | Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor |
title_fullStr | Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor |
title_full_unstemmed | Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor |
title_short | Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor |
title_sort | characterisation of (r)-2-(2-fluorobiphenyl-4-yl)-n-(3-methylpyridin-2-yl)propanamide as a dual fatty acid amide hydrolase: cyclooxygenase inhibitor |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4583449/ https://www.ncbi.nlm.nih.gov/pubmed/26406890 http://dx.doi.org/10.1371/journal.pone.0139212 |
work_keys_str_mv | AT gouveiafigueirasandra characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor AT karlssonjessica characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor AT deplanoalessandro characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor AT hashemiansanaz characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor AT svenssonmona characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor AT fredrikssonsundbommarcus characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor AT congiucenzo characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor AT onnisvalentina characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor AT fowlerchristopherj characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor |